|
Friday, November 2
_________________________________________________________________ |
12:00 PM - 6:00 PM
Amphitheater Lobby
Ground Floor
|
Badge Pick-Up (No onsite registration.) |
12:00 PM - 1:00 PM
Amphitheater Lobby
|
Box Lunch and Networking
There will be a limited number of box lunches available, first-come first-served. |
1:00 PM - 1:15 PM
Amphitheater |
Welcome
Healthcare – A Diagnosis of the Crisis
|
1:15 - 2:30 PM
Amphitheater |
Business Model Innovation in the Healthcare Industry
- Clayton M. Christensen, MBA '79, DBA '92
Robert and Jane Cizik Professor of Business Administration
Harvard Business School
Much of the discourse on making our health care system accessible relates to insuring the uninsured – with the unspoken assumption that the level and rate of increase in costs are what they are. This isn't the case.
Technological enablers, coupled with business model innovation, have the promise of dramatically reducing the cost and improving the accessibility of quality health care. Professor Christensen will talk about what these innovations are, and how they can be implemented.
|
2:30 - 3:00
Ground Floor Lobby |
Coffee Break/Networking |
3:00 - 4:15 PM
Amphitheater |
Stent Wars: Which Technology Will Prevail?
Panel Discussion
- Moderator:
Barnaby Feder
Reporter
The New York Times
Current controversy in cardiology has been directed at coronary stents
designed
to treat arterial obstruction in patients with chest pain and heart attack.
Over the past decade, the stent business has grown into a 6 billion dollar market
and has diverted patients away from open heart surgery. The present debate is
anchored around whether this minimally invasive procedure and in particular,
the
more expensive drug-eluting stents are overused. Two versions of stents are
on
the market: the older bare-metal stents and drug-eluting stents, introduced in
2003 to prevent renarrowing of the coronary arteries. The drug-eluting
stents
cost about $ 2,200 each, 2-3 times the price of the bare-metal stents, and
current reports of fatal blood clots occurring years after treatment have
raised
real concerns. Sales in the industry are falling while a debate among physicians, the FDA, and patients continues.
- Rick Anderson
Company Group Chairman, Johnson & Johnson
Worldwide Franchise Chairman, Cordis Corporation
- William H. (Hank) Kucheman
Senior Vice President and Group President
Interventional Cardiology Group at Boston Scientific
- Laura Mauri, MD, MSc
Chief Scientific Officer
Harvard Clinical Research Institute
- Sean Salmon
Vice President and General Manager
Coronary
and Peripheral Business
Medtronic
|
4:15 - 4:45 PM
Ground Floor Lobby |
Coffee Break/Networking |
4:45 - 6:00 PM
Amphitheater |
Regenerative Medicine – Will Replacement Tissue Grown From the Patients’ Own Adult Stem Cells Disrupt the Pharmaceutical and Medtech Industries?
Panel Discussion
- Moderator:
Robert S. Huckman, PhD
Associate Professor of Business Administration
Harvard Business School
As the ethical controversies over human embryonic stem cells dominate the headlines, these entrepreneurs are quietly building the businesses that may well disrupt both the medical device and pharma/biotech industries. While there is no human embryonic stem cell therapy in clinical trials, all three of these companies are already in clinical trials and Tengion is seeking FDA approval.
- Anthony Atala, MD
Professor and Director
Wake Forest Institute for Regenerative Medicine
Founder, Tengion
- Marc Hedrick
President
Cytori Therapeutics
- Duncan J. Stewart, MD
CEO and Scientific Director
Ottawa Health Research Institute
|
6:15 PM - 7:15
Ground Floor Lobby
|
Welcome Reception
Drinks, Hors D'Oeuvres, Networking
|
7:15 PM - 9:30 PM
Elements Café |
HBS Health Welcome Dinner
|
| |
Saturday, November 3
__________________________________________________________________
|
7:30 AM - 6:00 PM
Amphitheater Lobby
Ground Floor |
Badge Pick-Up (No onsite registration.) |
7:30 - 8:45 AM
Elements Café |
Continental Breakfast |
8:45 - 9:00 AM
Amphitheater |
Opening Remarks and Introduction
|
9:00 - 9:45 AM
Amphitheater |
Emerging and Re-Emerging Infectious Diseases: The Perpetual Challenge to Global Health
- Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Dr. Fauci will discuss the continual evolution of microbial pathogens and their extraordinary capability to persist, emerge and re-emerge. The delicate balance between evolving microbes and the human species can only be maintained by robust public health measures such as disease surveillance, as well as by the development of new and improved countermeasures such as diagnostics, therapeutics and vaccines that result from biomedical research and industry development.
|
9:45 - 10:15 AM
Ground Floor Lobby |
Coffee Break/Networking |
10:15 AM - 11:45 PM
Amphitheater |
Public and Private Partnerships for Working with Emerging Threats
Panel Discussion
- Moderator:
Matthew Bishop
Chief Business Writer/American Business Editor
New York Bureau Chief
The Economist
- Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
- Alice Jacobs, MD
Chief Executive Officer
Intelligent Medical Devices
- Sara Sievers
Senior Program Officer, Global Health Advocacy
Gates Foundation
- Kirk Ririe
Founder
Idaho Technology
- Stephane Bancel
CEO
Biomerieux
Germs are global. They cross borders and socio-economic boundaries, evade current surveillance and diagnostics capabilities and are increasingly resistant to treatments and vaccines. Emerging and re-emerging infections pose major threats to both global health as well as to the global economy. New strains of HIV have evolved such that current diagnostic testing capabilities fail to detect them thus posing a serious threat to the safety of our blood supply. Consider extreme drug resistant TB, necrotizing fasciitis from superbugs, novel deadly strains of influenza that can evade our immune system and our vaccines. Precise identification of infections is critical for the development of good treatments and more importantly for prevention—vaccines. Public and private institutions have been responsible for fueling innovations in diagnostics and therapeutics to address these issues. To date, these extensive efforts have just begun to yield some promising solutions. In order to be most effective, it is essential for there to be joint collaboration between governments, academic centers and innovative enterprises, regional and global companies, foundations and other NGOs. Only through public-private partnerships will it be truly possible to develop a comprehensive and effective strategy for diagnosis, treatment and possible eradication of these infections. |
12:00 - 1:00 PM
Elements Café |
Luncheon |
1:00 - 1:45 PM
Amphitheater |
Challenges and Opportunities of Running a Global Organization in Healthcare
- Mark Schneider, MBA '93
Chairman of the Managing Board
Fresenius AG
Bad Homburg, Germany
This session explores differences in the degree of globalization of firms across healthcare segments, in particular pharmaceuticals, med tech and healthcare services. We will discuss obstacles to rapid globalization and suggest organizational strategies and corporate competencies that can help to overcome them. We will debate the tension between local adaptation and global aggregation/uniformity and suggest tools to help companies identify their adequate geographic scope and sources of true global competitive advantage.
|
1:45 - 3:15 PM
Amphitheater |
Disruptive Innovation in Healthcare Delivery
It is highly unlikely that we will be able to improve quality, address inequality and reduce the cost of healthcare without disruptive innovations. We will hear from two of the great practitioners of low cost/high convenience healthcare delivery in the US – Minute Clinic and Whole Health Management. We will get an understanding of which innovations in healthcare create the highest return on investment from Larry Keeley, President and co-founder of Doblin (a unit of Monitor Company) author of The Taming of the New and recognized by Business Week as one of the seven “Innovation Gurus” that are changing the field. The US examples will be compared with the surprisingly high level of innovation in the current National Health Service in the UK. The National Health Service in England has historically been unable to improve value because there has been profound collusion between the way in which demand for health care has been manifested and the way in which providers meet that demand The reforms of the last decade have provided the basis for competition against national prices between secondary care providers. Paul Corrigan’s talk will conclude with a discussion of the ambition of the NHS to provide a world class health service to the population of London a world class city.
|
3:15 - 3:45 PM
Ground Floor Lobby |
Coffee Break/Networking |
3:45 - 4:15 PM
Amphitheater |
Disruptive Innovation in Healthcare Delivery: Panel
|
4:15 - 5:00 PM
Amphitheater |
Why Is US Healthcare So Expensive, and What Can Be Done About It?
- Diana Farrell
Director
McKinsey Global Institute
Through comparison with 13 developed nations, the McKinsey Global Institute found that the United States spends $477 billion ($1,600 per capita) more than expected on health care than peer countries. Despite higher costs, the United States does not deliver objectively better quality and access for US citizens as a whole relative to peer countries. This session explores the opportunities for cost improvement that are as possible as they are necessary, given the pressures of fiscal imbalances, demographics, and rising health care costs. To be effective, reform in health care will need to apply sound principles on both the demand and supply side of the system.
|
5:00 - 5:15 PM
|
Break
|
5:15 - 6:00 PM
Amphitheater
|
Grand Panel: Conclusions for Advancing Global Healthcare
Synthesis of the Conference Led by Scott Hensley
- Moderator:
Scott Hensley
News Editor
The Wall Street Journal
- This conference has brought together some of the world’s greatest thinkers and greatest practitoners of the advancement of healthcare. In this session we will reassemble all the speakers, moderators and panelists from the conference on stage at once. This “Grand Panel” will be orchestrated by a leading journalist – Scott Hensley – to see what conclusions the attendees can reach and what actions they might take.
|
6:15 - 7:15 PM
Ground Floor Lobby |
Reception
Drinks, Hors D'Oeuvres, Networking |
7:15 - 9:30 PM
Elements Café |
8th Annual HBS Health Conference Dinner
Special Guest Speaker, John Crowley, MBA '97
Winner of Beatrice D. Ellerin Award for 2007
- John Crowley, MBA '97
President and CEO
Amicus Therapeutics
John Crowley's success leading biotech companies is only part of the picture. His unwavering mission to find a cure for his childrens’ Pompe disease is a compelling story of the power of determination, character and business acumen.
|
|
Sunday, November 4
________________________________________________________________ |
8:30 AM - 12:00 PM
Second Floor Lounge |
Badge Pick-Up (No onsite registration.) |
9:00 AM - 10:45 AM
Rooms 214, 216, 217 and Second Floor Conference Lounge
|
Roundtable Discussions
- Steven Wardell, MBA '00
Roundtable Chair, HBS Health Industry Alumni Association
Choose a roundtable according to your areas of interest, and discuss a specific healthcare topic over coffee, croissants and muffins.
|
10:45 - 11:30 AM
Amphitheater
|
Consumer-Driven Healthcare in Switzerland: Lessons for the US?
|
11:30 AM - 1:00 PM
Elements Café
|
Networking Brunch
|
|
Note: Program is preliminary and subject to change. |
